THE IMPACT OF SLIMMING PENS ON OBESITY TREATMENT AND THE CHALLENGES OF INDISCRIMINATE USE IN BRAZIL
DOI:
https://doi.org/10.63330/aurumpub.049-040Keywords:
GLP-1 analogs, Health policies, Obesity, Pharmacological treatment, Self-medicationAbstract
This chapter analyzes the impact of so-called “weight loss pens” on obesity treatment, emphasizing the challenges related to their indiscriminate use in Brazil. The objective is to discuss the therapeutic efficacy of these drugs, such as GLP-1 analogs, and to critically examine their use without proper medical prescription. The methodology is based on a narrative literature review, including clinical studies, national and international guidelines, and health surveillance data. The results show that these medications are effective in promoting weight loss and improving metabolic control, particularly in patients with obesity and comorbidities. However, there is a growing trend of aesthetic use and self-medication, which is associated with risks such as adverse effects, drug shortages, and inequitable access. It is concluded that, despite representing an important therapeutic advancement, it is essential to strengthen regulation, health education, and clinical monitoring to ensure the safe and equitable use of these technologies in the Brazilian context.
Downloads
References
AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes—2023. Diabetes Care, v. 46, supl. 1, p. S1–S291, 2023.
BRAY, George A.; KIM, Kyung Mook; WILDING, John P. H. Obesity: a chronic relapsing progressive disease process. Metabolism, v. 69, p. 1–3, 2017.
BRASIL. Ministério da Saúde. Vigitel Brasil 2023: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde, 2023.
DAVIES, Melanie J. et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, v. 397, n. 10278, p. 971–984, 2021.
FRIAS, Juan P. et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes. The New England Journal of Medicine, v. 385, n. 6, p. 503–515, 2021.
GIL, Antonio Carlos. Métodos e técnicas de pesquisa social. 7. ed. São Paulo: Atlas, 2019.
MARCONI, Marina de Andrade; LAKATOS, Eva Maria. Fundamentos de metodologia científica. 8. ed. São Paulo: Atlas, 2021.
MINAYO, Maria Cecília de Souza. O desafio do conhecimento: pesquisa qualitativa em saúde. 14. ed. São Paulo: Hucitec, 2014.
NOVO NORDISK. Relatório institucional sobre semaglutida e obesidade. Bagsværd: Novo Nordisk, 2022.
PI-SUNYER, Xavier et al. A randomized, controlled trial of liraglutide for weight management. The New England Journal of Medicine, v. 373, n. 1, p. 11–22, 2015.
RUBINO, Francesco et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine, v. 26, p. 485–497, 2020.
SOCIEDADE BRASILEIRA DE ENDOCRINOLOGIA E METABOLOGIA. Posicionamento oficial sobre o uso de análogos de GLP-1 no tratamento da obesidade. São Paulo: SBEM, 2022.
WADDEN, Thomas A. et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, v. 325, n. 14, p. 1403–1413, 2021.
WILDING, John P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, v. 384, n. 11, p. 989–1002, 2021.
WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: WHO, 2023.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
